Skip to main content
Equibles
RVMDW logo

RVMDW · Revolution Medicines, Inc.

Track RVMDW — free

Use RVMDW with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RVMDW.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.85 -0.52 (-5.55%) At close · Oct 26
Russell 1000 member Rebalance outlook locked
Market Cap
$40.08B
Shares
214.34M
Volume · Oct 26 18.53K Avg daily vol (3M) 39.62K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$8.85 Open$9.26 Day$8.85–9.35 Available close range$8.40–13.26 Avg vol 30d28K Last earningsNov 4, 2026 DataJul 2026–Oct 2026 Filing10-Q · Aug 5

The closing range uses available history since Jul 23, 2026; less than a full year is stored.

Up next

Next earnings call
Nov 4, 2026 Scheduled · in 1 wks
Latest filing: 10-Q
filed Aug 5, 2026
Q2 2026 earnings call transcript
call held Aug 5, 2026

Guidance & track record

Latest guidance · from the Earnings Call filed Aug 5, 2026
GAAP operating expenses · full-year 2026 GAAP Raised $2.1B – $2.2B
May 6, 2026 $1.7B – $1.8B changed to Aug 5, 2026 $2.1B – $2.2B
Prior guidance period ended · from the 8-K filed Nov 5, 2025
GAAP net loss · full year 2025 $1.03B – $1.09B
Non-cash stock-based compensation expense · full year 2025 $115M – $130M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
172 of 708 funds reported for Sep 30 · net +2.1M sh shares · +39 new
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
No short-interest data
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
708 holders — near 3-yr high, broad support
Price context
position in its available closing range
Range low $8 Now $9 · 9% Range high $13
vs 50-day avg -19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
aggregate principal amount of 0.50% convertible senior notes due 2033 issued $500M April 2026 —
committed, flexible capital remaining under Royalty Pharma funding arrangements 1.5B Q2 2026 —
confirmed overall response rate (ORR) for elironrasib plus standard of care in first-line RAS G1 85% Q2 2026 data cutoff May 11, 2026 —
disease control rate (DCR) for elironrasib plus standard of care in first-line RAS G12C NSCLC 97% Q2 2026 data cutoff May 11, 2026 —
disease control rate (DCR) for zoldonrasib plus standard of care in first-line RAS G12D NSCLC 100% Q2 2026 data cutoff May 11, 2026 —
efficacy evaluable patients in zoldonrasib plus standard of care NSCLC combination analysis 28 Q2 2026 data cutoff May 11, 2026 —
gross proceeds from April 2026 concurrent public offerings $2.23B April 2026 —
non-cash charge related to change in fair value of EQRx warrants $151M Q2 2026 —
overall response rate (ORR) for zoldonrasib plus standard of care in first-line RAS G12D NSCLC 82% Q2 2026 data cutoff May 11, 2026 —
patients analyzed in zoldonrasib plus standard of care NSCLC combination analysis 38 Q2 2026 data cutoff May 11, 2026 —
patients receiving daraxonrasib through Expanded Access Program 2,000 since opening of the Expanded Access Program through Q2 2026 —
progression-free rate at 6 months for elironrasib plus standard of care in first-line RAS G12C N 95% Q2 2026 data cutoff May 11, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RVMDW
Revolution Medicines, Inc.
this stock
$40.08B — — — —
VRTX
Vertex Pharmaceuticals Inc
 $130.00B +14.1% +46.2% 29.9 1.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.88B +4.6% +20.8% 19.9 2.1%
MRNA
Moderna, Inc.
 $79.39B +574.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $65.57B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
739
% held
108.0%
Reported
172 of 708
Top holder
BlackRock, Inc.
Held Float
View
Short & Settlement
Fails to Deliver
FTD shares
119
Value
$22.7K
As of
Sep 24, 2026
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-1.1B
EPS diluted
$-5.95
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 13, 2026
This year
17

Following FDA approval of RASONQUE™ (daraxonrasib), Revolution Medicines, Inc. borrowed a $250.0 million Tranche A Loan, paid a $5.0 million draw fee, and declined a potential $250.0 million Tranche 3 payment.

View
Proposed Sales
Value
$1.3M
Shares
6.3K
Filed
Sep 29, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 4, 2026
Last webcast
Aug 5, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
RVMDW +0.7% -21.1% — -22.6% —
SPY -0.1% 0.0% +5.8% +0.4% +12.2%
vs SPY +0.8% -21.1% — -23.0% —
Key facts CIK 1628171 CUSIP 76155X100 13F (30d) 1 filings 1 filers Visit website Investor relations